Semaglutide cuts childhood obesity rates in trial but may stunt growth, study shows
A trial of the weight‑loss drug semaglutide found nearly 40% of children aged six to 11 no longer obese after 68 weeks, while also showing reduced height gain and higher gastrointestinal side effects.
